D-0506-2026 Class II Ongoing

Recalled by Wells Pharma Of Houston LLC — Houston, TX

FDA drug recall D-0506-2026 was initiated by Wells Pharma Of Houston LLC on Apr 1, 2026 and is designated Class II. Reason for recall: cGMP deviations. The recall status is ongoing. Affected quantity: 150 syringes.

Recall details

Product Type
Drugs
Report Date
May 6, 2026
Initiation Date
Apr 1, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
150 syringes

Product description

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 mcg per mL), well pharma of Houston, NDC 73702-203-65.

Reason for recall

cGMP deviations.

Distribution pattern

U.S. Nationwide.

Code information

Lot 022326203650432; Exp Date 06/25/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0506-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0506-2026. Report a data issue: hello@regdatalab.com.